No menu items!

Biomm closes deal to supply Covid-19 drug ‘Leronlimab’ to Brazil

RIO DE JANEIRO, BRAZIL - Biomm informed, in a material fact sent to the Brazilian Securities and Exchange Commission (CVM) this evening, that it has entered into an exclusive agreement with the company CytoDyn Inc. for the potential supply of the drug Leronlimab in Brazil.

CytoDyn, headquartered in Vancouver, Washington (USA), is a biotechnology company that is in the process of developing innovative treatments for multiple therapeutic indications.

Considering the possible use of Leronlimab in the treatment of patients diagnosed with Covid-19 who are hospitalized and in need of oxygenation, CytoDyn has requested its emergency use from the FDA (Food . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?

Check out our other content